Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37090
Title: | The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial) | Authors: | LODEWIJCKX, Joy ROBIJNS, Jolien CLAES, Marithe Evens, Stijn Swinnen, Laura Lenders, Hilde Bortels, Sandra Nassen, Wendy Hilkens, Ruth Raymakers, Liesbeth Snoekx, Sylvana Hermans, Sylvia MEBIS, Jeroen |
Issue Date: | 2022 | Publisher: | Source: | SUPPORTIVE CARE IN CANCER, | Status: | Early view | Abstract: | Purpose The purpose of this study was to investigate the effectiveness of photobiomodulation (PBM) therapy for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients. Methods A prospective, randomized placebo-controlled pilot trial (NEUROLASER) was set up with 32 breast cancer patients who underwent chemotherapy (ClinicalTrials.gov; NCT03391271). Patients were randomized to receive PBM (n = 16) or placebo treatments (n = 16) (2 × /week) during their chemotherapy. The modified Total Neuropathy Score (mTNS), six-minute walk test (6MWT), Numeric pain Rating Scale (NRS), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Taxane (FACT/GOG-Taxane) were used to evaluate the severity of CIPN and the patients' quality of life (QoL). Outcome measures were collected at the first chemotherapy session, 6 weeks after initiation of chemotherapy, at the final chemotherapy session, and 3 weeks after the end of chemotherapy (follow-up). Results The mTNS score increased significantly over time in both the control and the PBM group. A significantly higher score for FACT/GOG-Taxane was observed in the PBM group during chemotherapy compared to the control group. Questions of the FACT/GOG-Taxane related to sensory peripheral neuropathy symptoms showed a significant increase in severeness over time in the control group, whereas they remained constant in the PBM group. At follow-up, a (borderline) significant difference was observed between both groups for the 6MWT and patients' pain level, in benefit of the PBM group. Conclusions This NEUROLASER trial shows promising results concerning the prevention of CIPN with PBM in breast cancer patients. Furthermore, a better QoL was observed when treated with PBM. | Keywords: | Chemotherapy;Peripheral neuropathy;Polyneuropathy;Photobiomodulation;Breast cancer | Document URI: | http://hdl.handle.net/1942/37090 | ISSN: | 0941-4355 | e-ISSN: | 1433-7339 | DOI: | https://doi.org/10.1007/s00520-022-06975-x | ISI #: | 000771320000003 | Rights: | The Author(s) 2022 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s00520-022-06975-x.pdf | Published version | 929.14 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
5
checked on Oct 14, 2024
Page view(s)
38
checked on Jun 14, 2022
Download(s)
34
checked on Jun 14, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.